logo-loader
viewCardiex Ltd

Full interview: CardieX CEO provides significant corporate update including participation in COVID clinical trial

 

CardieX (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive Vancouver to discuss a number of updates with the company including the use of their XCEL SphygmoCor device by researchers in a clinical study by the Artery Society on COVID and arterial stiffness.

Cooper discusses that study and also gave Proactive some new information regarding Swiss company Roche selecting CardieX co-development partner Blumio for a medical-grade diagnostic sensor pilot program and Blumio's new development agreement with Infineon.

Quick facts: Cardiex Ltd

Price: 0.023 AUD

ASX:CDX
Market: ASX
Market Cap: $17.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiex Ltd named herein, including the promotion by the Company of Cardiex Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CardieX completes world’s first medically reliable wearable...

CardieX (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive Vancouver to discuss details that the company has become the first in the world to derive unique and medically reliable heart and arterial health features from a PPG sensor. Cooper telling Proactive this technological...

4 weeks, 1 day ago

2 min read